Top Clinical Trials companies in China by Total Non-Current Liabilities
China
# |
Name |
Total Non-Current Liabilities |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
|---|---|---|---|---|---|---|---|
| 1 |
USD 487.02 M
|
Dec. 31, 2023 | USD 7.68 | -4.49% |
|
China |
|
| 2 |
USD 372.38 M
|
Dec. 31, 2023 | USD 2.18 | 5.57% |
|
China |
|
| 3 |
USD 210.65 M
|
Dec. 31, 2023 | USD 4.49 | -4.91% |
|
China |
|
| 4 |
USD 193.27 M
|
Dec. 31, 2023 | USD 0.20 | 3.38% |
|
China |
|
| 5 |
USD 153.31 M
|
Dec. 31, 2023 | USD 3.70 | -0.36% |
|
China |
|
| 6 |
USD 134.29 M
|
Dec. 31, 2023 | USD 1.76 | 1.76% |
|
China |
|
| 7 |
USD 90.77 M
|
Dec. 31, 2023 | USD 0.73 | 0.16% |
|
China |
|
| 8 |
USD 83.95 M
|
Dec. 31, 2023 | USD 0.37 | 3.22% |
|
China |
|
| 9 |
USD 81.96 M
|
Dec. 31, 2023 | USD 3.88 | -0.18% |
|
China |
|
| 10 |
USD 68.03 M
|
Dec. 31, 2023 | USD 1.06 | 0.95% |
|
China |
|
| 11 |
USD 50.27 M
|
Dec. 31, 2023 | USD 0.24 | 0.51% |
|
China |
|
| 12 |
USD 44.72 M
|
Dec. 31, 2023 | USD 0.45 | 3.81% |
|
China |
|
| 13 |
USD 39.26 M
|
Dec. 31, 2023 | USD 1.12 | 3.67% |
|
China |
|
| 14 |
USD 37.11 M
|
Dec. 31, 2023 | USD 2.63 | -0.26% |
|
China |
|
| 15 |
USD 27.91 M
|
Dec. 31, 2023 | USD 0.42 | 0.29% |
|
China |
|
| 16 |
USD 27.86 M
|
Dec. 31, 2023 | USD 0.18 | 1.43% |
|
China |
|
| 17 |
USD 25.63 M
|
Dec. 31, 2023 | USD 0.19 | 4.98% |
|
China |
|
| 18 |
USD 14.56 M
|
Dec. 31, 2023 | USD 0.93 | 0.35% |
|
China |
|
| 19 |
USD 13.71 M
|
Dec. 31, 2023 | USD 1.85 | NA |
|
China |
|
| 20 |
USD 5.27 M
|
Dec. 31, 2023 | USD 1.15 | 1.11% |
|
China |
|
| 21 |
USD 4.29 M
|
Dec. 31, 2023 | USD 0.15 | 2.66% |
|
China |
|
| 22 |
USD 1.46 M
|
Dec. 31, 2023 | USD 0.66 | -1.16% |
|
China |
|
| 23 |
USD 1.16 M
|
Dec. 31, 2023 | USD 6.58 | 0.30% |
|
China |
|
| 24 |
USD 585.00 K
|
Dec. 31, 2023 | USD 0.97 | NA |
|
China |
Frequently Asked Questions
-
Which Clinical Trials company in China has the highest Total Non-Current Liabilities ?
The Clinical Trials company in China with the highest Total Non-Current Liabilities is Akeso, Inc. (HKSE: 9926.HK) at USD 487.02 M.
-
Which Clinical Trials company in China has the lowest Total Non-Current Liabilities ?
The Clinical Trials company in China with the lowest Total Non-Current Liabilities is Connect Biopharma Holdings Limited (NasdaqGM: CNTB) at USD 585.00 K.
-
What are the top 10 Clinical Trials companies in China by Total Non-Current Liabilities ?
The top 10 Clinical Trials companies in China by Total Non-Current Liabilities are Akeso, Inc., Shanghai Henlius Biotech, Inc., Ascentage Pharma Group International, Hua Medicine (Shanghai) Ltd., Hangzhou Tigermed Consulting Co., Ltd., RemeGen Co., Ltd., InnoCare Pharma Limited, Lepu Biopharma Co., Ltd., Keymed Biosciences Inc. and I-Mab.
-
What are the bottom 10 Clinical Trials companies in China by Total Non-Current Liabilities ?
The bottom 10 Clinical Trials companies in China by Total Non-Current Liabilities are Connect Biopharma Holdings Limited, Burning Rock Biotech Limited, ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Kindstar Globalgene Technology, Inc., Mega Genomics Limited, Adagene Inc., Staidson (Beijing) BioPharmaceuticals Co., Ltd., Jacobio Pharmaceuticals Group Co., Ltd., JW (Cayman) Therapeutics Co. Ltd and Alphamab Oncology.
